We performed an unsupervised transcriptomic analysis of CD8+ cells isolated from patients enrolled after a first demyelinating episode into a randomised, double-blind, placebo-controlled clinical trial (STAyCIS14) that tested the effect of atorvastatin on relapse in patients in the earliest clinical phase of MS. Here, CD8A is linked to myeloid sarcoma.